GRCE (Grace Therapeutics) Stock Based Compensation: $0.80 Mil (TTM As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.37
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Stock Based Compensation?

Grace Therapeutics GRCE +5.57% 31 Stock Based Compensation is $0.80 Mil as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Grace Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $0.18 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.80 Mil.

Grace Therapeutics Stock Based Compensation Related Terms

Grace Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Stock Based Compensation Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 1.81 0.91 0.73 0.80

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.30 0.21 0.11 0.18
GRCE
31GF Score
Grace Therapeutics Inc GRCE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.80 Mil.

What does a Stock Based Compensation of $0.80 Mil mean?
Grace Therapeutics (GRCE) has a Stock Based Compensation of $0.80 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Grace Therapeutics and its competitors.
Is Grace Therapeutics' Stock Based Compensation too high?
Grace Therapeutics' current Stock Based Compensation is $0.80 Mil. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Stock Based Compensation compare to INMB and ABVC?
Grace Therapeutics' Stock Based Compensation of $0.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Grace Therapeutics and its competitors. Grace Therapeutics's current Stock Based Compensation is $0.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Stock Based Compensation of $0.80 Mil. The current Stock Based Compensation is $0.80 Mil. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Stock Based Compensation is $0.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.37
Price